Patents by Inventor Joseph L. Goldstein
Joseph L. Goldstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160068840Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.Type: ApplicationFiled: July 8, 2015Publication date: March 10, 2016Inventors: Juergen SOUTSCHEK, Pamela TAN, Jay D. HORTON, Michael S. BROWN, Joseph L. GOLDSTEIN, Young-Ah MOON
-
Patent number: 9102940Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.Type: GrantFiled: January 17, 2013Date of Patent: August 11, 2015Assignees: Alnylam Pharmaceuticals, Inc., Board of Regents, The University of Texas SystemInventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
-
Patent number: 8383805Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.Type: GrantFiled: April 5, 2011Date of Patent: February 26, 2013Assignees: Alnylam Pharmaceuticals, Inc., Board of Regents, The University of Texas SystemInventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
-
Patent number: 8329745Abstract: Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules of the general formula: Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition.Type: GrantFiled: September 6, 2011Date of Patent: December 11, 2012Assignee: Board of Regents, The University of Texas SystemInventors: Patrcik G. Harran, Michael S. Brown, Joseph L. Goldstein, Jing Yang, Tong-Jin Zhao
-
Publication number: 20110318807Abstract: Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules. Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition.Type: ApplicationFiled: September 6, 2011Publication date: December 29, 2011Inventors: Patrick G. Harran, Michael S. Brown, Joseph L. Goldstein, Jin Yang, Tong-Jin Zhao
-
Patent number: 8013015Abstract: Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules. Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition.Type: GrantFiled: October 1, 2009Date of Patent: September 6, 2011Assignee: Board of Regents, The University of Texas SystemInventors: Patrcik G. Harran, Michael S. Brown, Joseph L. Goldstein, Jing Yang, Tong-Jin Zhao
-
Patent number: 8003342Abstract: Disclosed are methods and compositions for the identification of inhibitors of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21ras. Also disclosed is a families of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme.Type: GrantFiled: April 18, 1991Date of Patent: August 23, 2011Assignee: Board of Regents, The University of Texas SystemInventors: Michael S. Brown, Joseph L. Goldstein, Yuval Reiss
-
Publication number: 20110184047Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.Type: ApplicationFiled: April 5, 2011Publication date: July 28, 2011Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
-
Patent number: 7919613Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.Type: GrantFiled: March 29, 2010Date of Patent: April 5, 2011Assignees: Alnylam Pharmaceuticals, Inc., Board of Regents, the Unversity of Texas SystemInventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
-
Publication number: 20100184829Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.Type: ApplicationFiled: March 29, 2010Publication date: July 22, 2010Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
-
Patent number: 7737266Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.Type: GrantFiled: September 18, 2007Date of Patent: June 15, 2010Assignees: Board of Regents, The University of Texas System, Alnylam Pharmaceuticals, Inc.Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
-
Publication number: 20100086955Abstract: Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules. Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition.Type: ApplicationFiled: October 1, 2009Publication date: April 8, 2010Inventors: Patrcik G. Harran, Michael S. Brown, Joseph L. Goldstein, Jing Yang, Tong-Jin Zhao
-
Publication number: 20090170141Abstract: Ghrelin is acylated ghrelin O-acyltransferase. Ghrelin O-acyltransferase assays comprise contacting a mixture of ghrelin and recombinant ghrelin O-acyltransferase with an agent; and detecting a resultant decrease in acylation of the ghrelin by the acyltransferase.Type: ApplicationFiled: December 29, 2007Publication date: July 2, 2009Inventors: Michael S. Brown, Joseph L. Goldstein, Nick V. Grishin, Jing Yang
-
Patent number: 7544466Abstract: Ghrelin is acylated by ghrelin O-acyltransferase. Ghrelin O-acyltransferase assays comprise contacting a mixture of ghrelin and recombinant ghrelin O-acyltransferase with an agent; and detecting a resultant decrease in acylation of the ghrelin by the acyltransferase.Type: GrantFiled: December 29, 2007Date of Patent: June 9, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Michael S. Brown, Joseph L. Goldstein, Nick V. Grishin, Jing Yang
-
Publication number: 20090093426Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.Type: ApplicationFiled: September 18, 2007Publication date: April 9, 2009Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
-
Patent number: 7223787Abstract: Permissiveness of human cells to replication of susceptible pathogenic human viruses is reduced by treating the cells with a selective inhibitor of prenylation of a host cell protein. Target viruses, especially Flaviviridae, are predetermined to lack a CXXX box and prenylated viral protein, and to be replication-dependent on host protein prenylation. The general method comprises (a) contacting human cells subject to infection by the virus with an effective amount of a selective inhibitor of a prenylation enzyme of the cells; and (b) confirming a resultant reduction in permissiveness of the cells to replication of the virus. Targeted enzymes include prenyl biosynthetic enzyme like HMG CoA reductase farnesyl and/or geranylgeranyl transferase enzymes.Type: GrantFiled: October 21, 2003Date of Patent: May 29, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Michael S. Brown, Jin Ye, Chunfu Wang, Rhea Sumpter, Jr., Joseph L. Goldstein, Michael Gale, Jr.
-
Patent number: 7172862Abstract: Agents that modulate an interaction of an FBL2 protein with an NS5A or NS5B Flaviviridae protein in a mixture are identified by contacting the mixture with a candidate agent under conditions wherein but for the presence of the agent, the FBL2 protein and the Flaviviridae protein engage in a reference interaction; and detecting an agent-biased interaction. Flaviviridae replication is inhibited by contacting a Flaviviridae-infected cell with an FBL2-specific reagent; and detecting a resultant Flaviviridae replication inhibition.Type: GrantFiled: May 4, 2005Date of Patent: February 6, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Michael J. Gale, Jr., Michael S. Brown, Joseph L. Goldstein, Chunfu Wang, Jin Ye
-
Patent number: 6936431Abstract: Disclosed are methods and compositions for the identification, characterization and inhibition of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21ras. Also disclosed is a families of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme.Type: GrantFiled: February 27, 2002Date of Patent: August 30, 2005Assignee: Board of Regents, The University of Texas SystemInventors: Michael S. Brown, Joseph L. Goldstein, Yuval Reiss
-
Patent number: 6790633Abstract: Disclosed are methods and compositions for the identification, characterization and inhibition of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21ras. Also disclosed is a families of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme.Type: GrantFiled: September 19, 2000Date of Patent: September 14, 2004Inventors: Michael S. Brown, Joseph L. Goldstein, Yuval Reiss
-
Patent number: 6649593Abstract: Compounds, compositions and methods are provided for the inhibition of S1 protease and for the modulation of cholesterol homeostasis in a cell.Type: GrantFiled: October 6, 2000Date of Patent: November 18, 2003Assignees: Tularik Inc., Board of Regents, University of Texas SystemsInventors: Juan C. Jaen, Leping Li, Michael S. Brown, Joseph L. Goldstein, Dong Cheng